Inl Med - Endcrn Diabetes Clin

Research output

Research output per year 1966 1978 1980 1988 1991 1992 1998 2002 2003 2004 2005 2006 2007 2008 2009 2011 2013 2014 2023

• 289 Article
• 32 Review article
• 18 Letter
• 13 Editorial
• 21 More
  • 10 Comment/debate
  • 5 Conference contribution
  • 4 Short survey
  • 2 Chapter

Research output per year

Research output per year

Search results

• 2019

  Erratum: Baseline characteristics of the Vitamin D and type 2 diabetes (D2D) study: A contemporary prediabetes cohort that will inform diabetes prevention efforts (Diabetes Care (2018) 41 (1590–1599) DOI: 10.2337/dc18-0240)

  LeBlanc, E. S., Pratley, R. E., Dawson-Hughes, B., Staten, M. A., Sheehan, P. R., Lewis, M. R., Peters, A., Kim, S. H., Chatterjee, R., Aroda, V. R., Chadha, C., Neff, L. M., Brodsky, I. G., Rosen, C., Desouza, C. V., Foreyt, J. P., Hsia, D. S., Johnson, K. C., Raskin, P., Kashyap, S. R., & 6 othersO’Neil, P., Phillips, L. S., Rasouli, N., Liao, E. P., Robbins, D. C. & Pittas, A. G., Dec 1 2019, In: Diabetes care. 42, 12, p. 2347 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Ergocalciferols 100%
  • Prediabetic State 91%
  • Type 2 Diabetes Mellitus 53%
  • Cardiovascular Diseases 51%
  • Hypertension 46%
• 2015

  Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

  Rigby, M. R., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Patel, C. M., Griffin, K. J., Tsalikian, E., Gottlieb, P. A., Greenbaum, C. J., Sherry, N. A., Moore, W. V., Monzavi, R., Willi, S. M., Raskin, P., Moran, A., Russell, W. E., Pinckney, A., Keyes-Elstein, L., & 7 othersHowell, M., Aggarwal, S., Lim, N., Phippard, D., Nepom, G. T., McNamara, J. & Ehlers, M. R., Feb 1 2015, In: Diabetes Technology and Therapeutics. 17, p. S81-S82

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
• 2014

  Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicenter, randomized double-masked, placebo-controlled trials

  Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., Sanda, S., Schatz, D., Wherrett, D., Wilson, D. M., Krischer, J. P., Skyler, J. S., Pickersgill, L., De Koning, E., Ziegler, A. G., Böehm, B., & 11 othersBadenhoop, K., Schloot, N., Bak, J. F., Pozzilli, P., Mauricio, D., Donath, M. Y., Castaño, L., Wägner, A., Lervang, H. H., Perrild, H. & Mandrup-Poulsen, T., 2014, In: Diabetes Technology and Therapeutics. 16, SUPPL. 1, p. S87

  Research output: Contribution to journal › Comment/debate › peer-review
• 2013

  Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recentonset type 1 diabetes: A randomized double-blind trial

  Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., Monzavi, R., Moran, A., Orban, T., Palmer, J. P., Raskin, P., Rodriguez, H., Schatz, D., Wilson, D. M., Krischer, J. P. & Skyler, J. S., Jun 1 2013, In: Diabetes Technology and Therapeutics. 15, SUPPL.1, p. S115-S116

  Research output: Contribution to journal › Comment/debate › peer-review

• Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere insulin or usual antidiabetes treatment: A randomized trial

  Raskin, P., Heller, S., Honka, M., Chang, P. C., Boss, A. H., Richardson, P. C. & Amin, N., Jun 1 2013, In: Diabetes Technology and Therapeutics. 15, SUPPL.1, p. S56

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
• 2010

  Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)

  Raskin, P. & Mohan, A., Sep 2010, In: Expert Opinion on Pharmacotherapy. 11, 13, p. 2269-2271 3 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Exenatide 100%
  • Type 2 Diabetes Mellitus 55%
  • Safety 42%
  • Glucagon-Like Peptide-1 Receptor 31%
  • Subcutaneous Injections 25%
  8 Scopus citations

• Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

  Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M. & Blonde, L., Mar 1 2010, In: Diabetes care. 33, 3, 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review
  13 Scopus citations
• 2003

  Erratum: Repaglinide vs. Nateglinide Metformin Combination Study Group: Efficacy and safety of combination therapy: Repaglinide plus metformin versus nateglinide plus metformin (Diabetes Care (2003) 26 (2063-2068))

  Raskin, P., Klaff, L., McGill, J., South, S. A., Hollander, P., Khutoryansky, N. & Hale, P. M., Sep 1 2003, In: Diabetes care. 26, 9, p. 2708 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2001

  Idiopathic type 1 diabetes in Dallas.

  Piñero-Piloña, A., Litonjua, P., Aviles-Santa, L. & Raskin, P., Nov 2001, In: Diabetes care. 24, 11, p. 2013 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
• 1992

  Tight glycemic control? Negative.

  Raskin, P., Feb 1992, In: Hospital practice (Office ed.). 27 Suppl 1, p. 21-24 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Blood Glucose 100%
  1 Scopus citations